Home → Focus

FDA Approves First Generic Truvada in U.S. Print E-mail
Written by FHI's Week in Review   
Sunday, 11 June 2017 15:30

Robert Lowes delivers news (login/complimentary subscription required) from the FDA on June 09, 2017:

The U.S. Food and Drug Administration (FDA) has approved the first generic version of emtricitabine/tenofovir disoproxil (Truvada, Gilead Sciences) to both treat and prevent HIV infections in this country, the agency announced today.

According to Mr. Lowes:

The list price for Gilead Science's Truvada is roughly $1500 for a month's regimen of one pill per day, or about $18,000 a year, although health insurance and patient-assistance programs knock down the price considerably. Generic versions of Truvada in other countries cost as little as $70 a year, according to Mitchell Warren, executive director of AVAC, an international organization that promotes HIV prevention.

Read more in the current issue of Week in Review>>

Last Updated on Monday, 12 June 2017 15:34
If Insurance Market Crashes, Can Lawmakers Put The Pieces Back Together? Print E-mail
Written by Julie Rovner | KHN   
Saturday, 10 June 2017 17:58

In his high-stakes strategy to overhaul the federal health law, President Donald Trump is threatening to upend the individual health insurance market with several key policies. But if the market actually breaks, could anyone put it back together again?

The question is more than theoretical. The Trump administration has already acted to depress enrollment in Affordable Care Act plans, has instructed the IRS to back off enforcement of the requirement that most people have health insurance or pay a penalty and threatened to withhold billions of dollars owed to insurance companies. All of those actions make it more difficult for insurers to enroll the healthy people needed to offset the costs of the sick who make it a priority to have coverage.

The president himself has made his strategy clear in interviews and tweets. "The Democrats will make a deal with me on healthcare as soon as ObamaCare folds...

Read More

Last Updated on Wednesday, 12 July 2017 10:42
Solving the Healthcare Conundrum: Neither the capitalists nor the government offer much hope Print E-mail
Written by FHI's Week in Review   
Monday, 05 June 2017 13:28
Entitled Dirty, Dingy Hospitals: Doctors Blame Debt-Fueled Takeovers (posted 6.1.17), Bloomberg authors John Lauerman and David Welch examine the situation at Community Health System (CHS), one of the nation's leading operators of general acute care hospitals. CHS is facing increasing criticism for prioritizing dept repayment over investments in facilities and quality initiatives.
Meanwhile, the Veterans Affairs Secretary has issued a blunt assessment of care for veterans. In a 5.31.17 press briefing at the White House, VA Secretary David Shulkin ran through his agency's priorities for fixing its myriad challenges.
The article in Bloomberg clearly illustrates the dangers created by for-profit health systems while the VA Secretary's briefing plainly details the problems associated with government run health systems.

Read more in the current issue of Week in Review>>

Last Updated on Wednesday, 28 June 2017 09:25
Primary Care Offers on the Rise, Including Salary and Signing Bonuses Print E-mail
Written by FHI's Week in Review   
Monday, 29 May 2017 13:34

The Medicus Firm, a national physician search firm headquartered in Dallas, released its 2nd annual primary care and advanced practice placement compensation summary report May 23, 2017.

According to the report, average total compensation packages offered to primary care physicians, including signing bonus, increased from $226,755 in 2015, to $257,533 in 2016. This includes family medicine physicians and internal medicine physicians in communities of all sizes, across the country.

Read more in the current issue of Week in Review>>

Last Updated on Friday, 16 June 2017 16:47
6 Tricks Used By Pharma Marketers Print E-mail
Written by Martha Rosenberg | KevinMD   
Monday, 29 May 2017 00:00

Long before the Internet and direct-to-consumer advertising, the medical profession tried to reassure people about their health concerns. Remember "take two aspirins and call me in the morning?"

Flash forward to today's online "symptom checkers." They are quizzes to see if someone has a certain disease and exhortations to see their doctor even if they feel fine. Once drug makers discovered that health fears and even hypochondria sell drugs, there seems to be no end to the new diseases, symptoms and risks people need to worry about.

In fact, since drug ads began on TV, Americans take so many drugs it inspires satirical T-shirts like the one that says:

     "I take aspirin for the headache caused by the Zyrtec I take for the hay fever I got from Relenza for the uneasy stomach from the Ritalin I take for the short attention span caused by the Scopoderm I take for the motion sickness I got from the Lomotil I take for the diarrhea caused by the Xenical for the uncontrolled weight gain from the Paxil I take for the anxiety from Zocor I take for my high cholesterol because exercise, a good diet and regular chiropractic care are just too much trouble."

Here are some of the ways ads use fear to keep the public buying drugs...

Read More

Last Updated on Tuesday, 30 May 2017 18:09
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 114

Website design, development, and hosting provided by